Ovagen Peptide Dosage Chart: 2mg Course & Vial Math

Ovagen is the synthetic tripeptide Glu-Asp-Leu (EDL), and no clinical trial has established a human dose for it. A widely circulated practitioner peptide reference lists it with the other Khavinson bioregulators on one shared protocol: a 20mg vial with 2mL of bacteriostatic water, 2mg (20 units) once daily for 30 consecutive days, then two months off, repeated two to three times a year. Self-reported community sources also describe shorter 10-20 day courses.

One mismatch shapes this whole guide. Ovagen is sold as a liver and gut bioregulator, yet the PubMed-indexed research on the EDL sequence is almost entirely kidney research, in rats and cell cultures, from a single Russian research network. The figures below are reported conventions, not doses derived from that work.

Research-context information only. Ovagen is a research peptide. Protocols, doses, and reactions reported below come from published research and self-reported community sources. This article reports what has been documented, not what should be done. Consult a licensed physician for personal medical decisions.

Ovagen is a three-amino-acid peptide from the St. Petersburg bioregulator program, listed by its vendor as C15H25N3O8 (375.37 g/mol). This guide covers the reported course, the reconstitution math and where each number comes from.

Quick Reference: Practitioner-Reported Protocol

Where the 2mg figure comes from: it is the shared bioregulator line in a practitioner peptide reference (the Jay Campbell / Hunter Williams cheat sheet), not a number taken from an Ovagen study. For the compound profile and current vendor pricing, see the Ovagen peptide page.

Cycling Details

The course-and-pause pattern is inherited from the Russian bioregulator tradition. The idea is that short peptides act as brief signals rather than drugs that need steady blood levels. The developers have described this framework across decades of their own work (Khavinson & Anisimov, 2009). Practitioner references run a 30-day course followed by a two-month break. Self-reported community protocols often shorten the course to 10-20 days. No study has compared course lengths for synthetic EDL, so neither pattern has been tested in people.

Routes of Administration

• Subcutaneous (SC): the route most commonly described in community sources for the reconstituted 20mg research vial.
• Intramuscular (IM): occasionally described in community sources, carried over from how injectable Russian bioregulator preparations were historically given.
• Oral capsules: sold in some markets under bioregulator names. They are a different format from the injectable research vial, and the two should not be read as interchangeable.

No route has been validated for synthetic Ovagen. US vendors sell the vial labeled for laboratory research only.

Reconstitution Quick Reference

The community-circulated arithmetic: 20mg ÷ 2mL = 10mg/mL, so 2mg is 0.2mL, or 20 units on a 100-unit insulin syringe. By that arithmetic, a 30-day course at the reported amount would total 60mg, or three 20mg vials. Community notes describe swirling gently rather than shaking, then refrigerating at 2-8°C.

These figures report how community sources describe the arithmetic. They are not a preparation instruction. Vendors label these vials for research use only; the schedules on this page are community- and practitioner-reported, not labeled directions.

Affiliate disclosure: vendor links in this article are affiliate links. The Peptide Catalog may earn a commission if you buy through them, at no additional cost to you.

Ready to buy? The Ovagen source we track publishes certificates of analysis; see our Ovagen sources page.

Where These Numbers Come From

The short answer: none of the dose figures above come from an Ovagen study. They come from a practitioner reference that applies one protocol to the whole Khavinson family, and from community convention.

What the EDL research actually studied. The indexed papers on the Glu-Asp-Leu sequence are kidney papers, almost all from the Khavinson network and its collaborators:

• In aging renal cell cultures, EDL (and the related tripeptide AED) increased cell proliferation, lowered the aging markers p16, p21 and p53, and raised SIRT-6 (Khavinson et al., 2014, PMID 25946838). A companion culture study, where EDL appears under the lab code T-35, identified the gelatinase MMP-14 as its target (Khavinson et al., 2014, PMID 24958378).
• In rats with cisplatin-induced acute kidney failure, EDL normalized urine output, creatinine excretion and filtration rate, which the authors described as a potent nephroprotective effect (Zamorskii et al., 2015, PMID 26515176).
• In rat models of gentamicin nephropathy and ischemia-reperfusion injury, EDL reduced proteinuria and lipid peroxidation and prevented oliguria (Zamorskii et al., 2017, PMID 28744634).
• In old rats, EDL raised urine output 1.2-1.4-fold and sodium excretion 1.6-fold, with no nephrotoxic findings on tissue examination (Zamorskii et al., 2018, PMID 30607912).

Those abstracts report effects, not doses that translate to people. None of them involved human subjects, and none studied the liver.

The liver framing. Vendors and secondary sources present Ovagen as a liver and gastrointestinal bioregulator. We searched PubMed for the EDL sequence and found no indexed study of the synthetic tripeptide in liver tissue. The liver claim may rest on Russian-language or patent material we could not verify, so this guide does not repeat it as a finding.

Extract versus synthetic. The Khavinson program made tissue-derived polypeptide complexes (extracts) and short synthetic peptides. The kidney studies tested them separately: a polypeptide complex isolated from calf kidney alongside synthetic EDL, with different results for each (Khavinson et al., 2014, PMID 24958378; Zamorskii et al., 2015, PMID 26515176). Data on an extract do not transfer automatically to the synthetic 20mg research vial, and the reverse holds too.

A name collision. "Ovagen" is also a veterinary FSH hormone product used for superovulation in sheep and cattle research (Gonzalez-Bulnes et al., 2002, PMID 12374130). Most PubMed hits for the word "Ovagen" are about that hormone, not the tripeptide.

The proposed mechanism. The developers' model holds that ultrashort peptides enter cells and interact with DNA and histones to shift gene expression (Khavinson et al., 2021, PMID 34834147). Molecular modeling suggests peptides of this size could be carried into cells by the LAT1, LAT2 and PEPT1 transporters (Khavinson et al., 2023, PMID 36979488). Both papers come from the originating group, and neither is a dosing study.

Stacking Protocols

Community sources sometimes run Ovagen in the same course as other Khavinson-family peptides on a "different tissue, different peptide" rationale. These pairings are self-reported and have no trial support.

No Ovagen combination has been studied in people. The table reports community descriptions, not a regimen.

Side Effects & Safety

• No human safety data exist for synthetic Ovagen. It is sold labeled "not for human consumption."
• The rat kidney studies above reported no nephrotoxic findings at the doses tested. Animal tolerability is not the same as human safety.
• Injection-site redness or soreness is the effect most often mentioned in self-reported community sources.
• Long-term effects of repeated courses are unknown.
• Sterile handling and reconstitution hygiene are the practical concerns community sources raise most often.

mg to Units Conversion

On a U-100 insulin syringe, 1 unit is 0.01mL. The draw depends on how much water went into the vial.

Dilution A: 20mg vial + 2mL BAC water (10mg/mL)

Dilution B: 20mg vial + 1mL BAC water (20mg/mL), a more concentrated mix with smaller draw volumes

Only the 2mg row matches the practitioner figure; the other rows are arithmetic reference points, not amounts a cited source reports. These conversions reflect the dilutions documented in community reconstitution protocols. They report how the math is described, not a recommended dosing schedule.